Welcome to our dedicated page for Summit Therapeutics SEC filings (Ticker: SMMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Summit Therapeutics Inc. (SMMT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. Summit is a Delaware-incorporated biopharmaceutical oncology company listed on The Nasdaq Stock Market LLC, and its filings offer detailed information on clinical progress, financing activities, and material agreements.
Among the key documents are Form 8-K current reports, where Summit has described material events such as private placements of common stock, amendments to its at-the-market distribution agreement, and clinical and scientific updates related to ivonescimab. For example, the company filed 8-Ks summarizing Akeso’s Phase III HARMONi-A results in EGFR-mutated NSCLC, including overall survival hazard ratios and median survival data for ivonescimab plus chemotherapy versus chemotherapy alone, and reporting presentations of HARMONi data at major oncology conferences.
Other 8-K filings detail Summit’s entry into securities purchase agreements for a significant private placement of common stock to institutional and individual investors, including insiders and Akeso, and amendments to its distribution agreement with a sales agent to expand its at-the-market equity offering capacity. Filings also cover operational matters such as a sub-sublease for office space in Palo Alto, California, and inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
Investors can also review references to Summit’s shelf registration on Form S-3 and related prospectus supplements that support its at-the-market program, as cited in the company’s 8-K disclosures. These filings help explain how Summit finances its global Phase III development program for ivonescimab and other corporate initiatives.
On Stock Titan, each new Summit filing is captured from EDGAR and paired with AI-powered summaries that highlight the main points, such as clinical trial outcomes, capital-raising terms, and key contractual provisions. Users can quickly understand the implications of a filing without reading the full legal text, while still having direct access to the original documents for deeper analysis.
Summit Therapeutics Inc. director Robert F. Booth reported receiving two stock option grants on January 2, 2026. He was granted stock options to purchase 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, as long as he remains a non-salaried director on each vesting date.
Booth was also granted stock options covering 7,180 shares of common stock, also at an exercise price of $17.52 per share and expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 following his election as a director and were issued under the company’s Director Retainer Option Election Plan in lieu of $62,900 in retainer fees.
Summit Therapeutics Inc. reported that director Kenneth A. Clark received new stock option awards. On January 2, 2026, he was granted 35,000 stock options with an exercise price of $17.52 per share, vesting in four quarterly installments during the year of grant, as long as he continues serving as a non-salaried director on each vesting date. On the same date, he also received a separate grant of 17,796 stock options with the same exercise price, issued under the company’s Director Retainer Option Election Plan in lieu of $155,900 of cash retainer fees. All reported options are held directly.
Summit Therapeutics Inc. reported that director Alessandra Cesano received new stock option awards. On 01/02/2026, she was granted a stock option for 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on 01/02/2036. These shares vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, as long as she continues serving as a non-salaried director.
She was also granted a separate stock option for 3,219 shares of common stock at the same $17.52 exercise price, expiring on 01/02/2036. This option was issued under the company’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200 and vests in four quarterly installments on March 31, June 30, September 30 and December 31 following her election, contingent on continued board service.
Summit Therapeutics (SMMT) reported that its partner Akeso published final overall survival results from the Phase III HARMONi-A trial in China. The study tested ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after EGFR TKI therapy.
Ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit with a hazard ratio of 0.74 (95% CI: 0.58, 0.95; p=0.019). Median OS was 16.8 months (95% CI: 14.5, 20.0) versus 14.1 months (95% CI: 12.8, 16.3) for chemotherapy alone. The analysis used an April 2025 data cut-off and had a 32.5‑month median follow-up. Summit furnished these data via a press release attached as Exhibit 99.1.
Summit Therapeutics (SMMT) reported an insider transaction by director Yu Xia. On 10/21/2025, she acquired 533,617 shares of common stock at $18.74 per share in a private placement pursuant to a definitive agreement, anticipated to close on or about 10/23/2025. After the transaction, 32,057,147 shares were beneficially owned indirectly through Akeso, Inc. Dr. Xia disclaims beneficial ownership of Akeso’s holdings except to the extent of her pecuniary interest.
Summit Therapeutics (SMMT) insider transaction: Chief Accounting Officer Bhaskar Anand reported acquiring 26,680 shares of common stock at $18.74 per share on 10/21/2025. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Following the reported transaction, Anand beneficially owned 159,751 shares directly. Holdings include shares previously acquired through the company’s employee stock purchase plan.
Summit Therapeutics Inc. (SMMT) reported an insider purchase by its COO and CFO, who is also a director. On 10/21/2025, the reporting person acquired 53,361 shares of common stock at $18.74 per share, coded as an acquisition (A).
Following this transaction, the reporting person beneficially owned 3,073,603 shares, held directly. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Summit Therapeutics (SMMT) Co‑CEO, director, and 10% owner Robert W. Duggan reported acquisitions of common stock. He acquired 13,980,789 shares at $18.74 in a private placement pursuant to a definitive agreement dated October 21, 2025, anticipated to close on or about October 23, 2025. He also acquired 266,808 shares indirectly at $18.74 and purchased 26,680 shares at $18.74.
Following these transactions, he beneficially owned 570,073,879 shares directly and 25,724,474 shares indirectly via a trust, with additional indirect holdings of 76,680, 31,000, and 10,199,776 shares through family and related trusts.
Summit Therapeutics (SMMT) Co‑Chief Executive Officer and director Mahkam Zanganeh, a 10% owner, reported multiple share purchases dated 10/21/2025 tied to a private placement at $18.74 per share. Reported acquisitions include 266,808 shares by the Mahkam Zanganeh Revocable Trust, 26,680 shares for an immediate family member, and 13,980,789 shares by her spouse. The filing notes the transaction was pursuant to a definitive agreement and is anticipated to close on or about October 23, 2025. The report includes a standard disclaimer of beneficial ownership for certain indirect holdings.
Summit Therapeutics Inc. announced a private placement of 26,682,846 shares of common stock at $18.74 per share, matching the October 21, 2025 closing price, for aggregate gross proceeds of approximately $500.0 million. The financing is a primary issuance and is expected to close on or before October 28, 2025, subject to customary closing conditions.
Company leaders and employees participated, purchasing an aggregate of 14,514,402 shares, and Akeso, Inc. purchased 533,617 shares. The shares are being issued in reliance on Section 4(a)(2) and Regulation D exemptions. Summit agreed to file a registration statement to register the resale of these shares as soon as reasonably practicable and no later than December 19, 2025, and to use reasonable best efforts to have it declared effective.